Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma (Nasdaq: LYEL) said senior management will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 11:00 AM ET.

Rhea-AI Summary

Lyell Immunopharma (Nasdaq: LYEL) said senior management will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 11:00 AM ET. A live webcast will be available via the company investor website, with a replay posted after the presentation.

The presentation covers Lyell's late-stage CAR T-cell therapy pipeline and provides an opportunity for investor questions and management commentary.

Argus Apr 7 session

+0.41% close to close Open Argus

Details

News Market Reaction – LYEL

In the Apr 7 session, LYEL gained 0.41%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights LYEL’s participation in the 25th Annual Needham Virtual Healthcare Conf...

Analysis

This announcement highlights LYEL’s participation in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, offering investors another forum to hear from senior management. It follows recent earnings, clinical, and financing disclosures, as well as an S-3 registration for resale of existing shares. Investors may watch the webcast for any updates on the CAR T-cell pipeline, capital position, and timelines relative to the milestones described in recent SEC filings.

Key Figures

Conference edition: 25th Annual Conference date: April 14, 2026 Presentation time: 11:00 am ET

Conference edition

25th Annual

Needham Virtual Healthcare Conference

Conference date

April 14, 2026

Scheduled Needham conference presentation

Presentation time

11:00 am ET

Needham conference webcast start time

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Earnings and updates

   24h Move

   -14.2%

   Reported 2025 net loss and cash position alongside clinical and business updates.

2. Mar 09

   Private placement, CFO

   24h Move

   +13.5%

   Closed additional $50M equity tranche and appointed new Chief Financial and Business Officer.

3. Feb 23

   Investor conferences

   24h Move

   +6.1%

   Announced management participation in multiple early-March investor conferences.

4. Feb 12

   Phase 3 trial start

   24h Move

   +4.3%

   Initiated patient dosing in Phase 3 PiNACLE-H2H head-to-head CAR T trial.

5. Dec 07

   Clinical data update

   24h Move

   +12.3%

   Presented strong ronde-cel LBCL data with high ORR and CR rates at ASH.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car t-cell therapies

1 terms

car t-cell therapies medical

"advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients"

CAR T-cell therapies are treatments that remove a patient’s immune cells, reprogram them to recognize specific cancer markers, and return them to the body so they act like specially trained soldiers hunting tumor cells. They matter to investors because they can offer powerful, long-lasting benefits for hard-to-treat cancers but come with high development, manufacturing and regulatory costs, pricing and reimbursement uncertainty, and concentrated market risk that can drive big gains or losses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time.

A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the webcast will be available on the Company's website following the presentation date.

About Lyell

Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned presentation and participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact:

Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
pfenton@lyell.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lyell Immunopharma (LYEL) present at the Needham Virtual Healthcare Conference?

Lyell will present on April 14, 2026 at 11:00 AM Eastern Time. According to the company, senior management will participate in the 25th Annual Needham Virtual Healthcare Conference and take investor questions during the session.

How can investors watch the Lyell (LYEL) presentation on April 14, 2026?

Investors can watch a live webcast on the company's investor website at www.lyell.com. According to the company, a replay will also be posted on the website after the presentation for later viewing.

What topics will Lyell (LYEL) management likely cover at the April 14, 2026 presentation?

Management will discuss Lyell's late-stage CAR T-cell therapy pipeline and program updates. According to the company, the presentation is intended to provide program context and allow management to answer investor questions.

Will a replay of the Lyell (LYEL) Needham presentation be available after April 14, 2026?

Yes, a replay will be available on the company's investor website following the presentation. According to the company, attendees who miss the live session can access the recorded webcast on www.lyell.com.

Who from Lyell Immunopharma (LYEL) will present at the Needham Virtual Healthcare Conference?

Members of Lyell's senior management team will present and participate in the session. According to the company, senior executives will represent Lyell and address investor questions during the April 14, 2026 webcast.